Golimumab

證據等級: L5

預測適應症: 10 個

Golimumab: From Rheumatoid Arthritis to Rheumatoid Vasculitis

One-Sentence Summary

Golimumab is a fully human anti-TNF-α monoclonal antibody internationally approved for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The TxGNN model predicts it may be effective for Rheumatoid Vasculitis (score 99.73%), but the supporting evidence is weak and partly contradictory — none of the 3 clinical trials study vasculitis specifically, and one of the 6 literature reports documents anti-TNF therapy inducing vasculitis (Takayasu’s arteritis) rather than treating it.

Quick Overview

Item	Content
Original Indication	Rheumatoid arthritis (internationally approved; no formal registry record in this evidence pack — see Data Gap DG002)
Predicted New Indication	Rheumatoid Vasculitis
TxGNN Prediction Score	99.73%
Evidence Level	L4
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack (flagged as Data Gap DG002). Based on known information, golimumab is a fully human IgG1κ monoclonal antibody that neutralises tumour necrosis factor-alpha (TNF-α), and its efficacy in TNF-α–driven inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis) is well established internationally.

Rheumatoid vasculitis is a severe extra-articular manifestation of rheumatoid arthritis, and TNF-α is implicated in its pathogenesis, which is the surface-level rationale for this prediction — golimumab already treats the parent disease (RA), so treating a complication of RA is mechanistically plausible.

However, this evidence pack itself surfaces an important counter-signal: anti-TNF therapy has also been reported to induce vasculitis as a paradoxical adverse effect (see PMID 22999907, Takayasu’s arteritis occurring under anti-TNF therapy). None of the retrieved clinical trials study golimumab specifically in rheumatoid vasculitis. This should be treated as a safety signal requiring clarification, not confirmed treatment evidence.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01579006	N/A (observational)	Completed	184	Non-interventional RA study — note: evaluates tocilizumab (Actemra), not golimumab; general RA population, not vasculitis-specific
NCT05696106	N/A	Unknown	750,000	Registry study on risk of a second immune-mediated inflammatory disease (IMID) developing in patients with an existing IMID; not a golimumab efficacy trial
NCT07138898	Phase 2	Not yet recruiting	80	Perioperative immunosuppressant management in rheumatology patients undergoing shoulder arthroplasty; unrelated to vasculitis treatment

None of the identified trials directly study golimumab in rheumatoid vasculitis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
23557513	2013	Review	BMC Medicine	General review of biologic therapy (incl. anti-TNF agents) for autoimmune rheumatic diseases
31491879	2019	Network Meta-Analysis	Int J Mol Sci	36 RCTs comparing 5 TNF inhibitors (incl. golimumab) for reducing joint destruction in RA vs methotrexate; no vasculitis endpoint
27591827	2017	Observational	Semin Arthritis Rheum	Frequency and causes of end-stage renal disease in RA patients; not vasculitis- or golimumab-specific
22999907	2013	Case Report	Joint Bone Spine	Two cases of Takayasu’s arteritis (large-vessel vasculitis) occurring during anti-TNF therapy — a paradoxical adverse effect, opposite to the treatment hypothesis
23252659	2013	Case Report	Ocul Immunol Inflamm	Golimumab used successfully for Behçet disease-associated uveitis (a different vasculitic/inflammatory eye condition, not rheumatoid vasculitis)
29075910	2018	Case Report	Rheumatol Int	Pyoderma gangrenosum and septic arthritis in an RA patient on golimumab; discusses rheumatoid vasculitis as a background disease feature, not as a treatment outcome

Australia Market Information

No product currently registered (0 entries; market status: Not marketed).

Safety Considerations

No structured warnings, contraindications, or drug-interaction data were retrieved for this candidate (TFDA/PI extraction pending — see Data Gap DG001, classified as Blocking). Please refer to the TGA-approved Product Information (PI) for safety information.

Literature-derived signal worth noting: one case report in this evidence pack (PMID 22999907) describes anti-TNF therapy inducing large-vessel vasculitis (Takayasu’s arteritis) as a paradoxical adverse effect. This should be treated as a safety consideration for any vasculitis-related use, pending formal PI review.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence level is L4 with no trials specific to rheumatoid vasculitis, and one retrieved case report describes anti-TNF therapy inducing vasculitis rather than treating it — a direction that conflicts with the repurposing hypothesis. Combined with the Blocking-severity gap in TFDA safety data, this candidate does not meet the threshold to proceed.

To proceed, the following is needed:

TFDA/PI-equivalent warnings and contraindications (Data Gap DG001, Blocking)
Confirmed mechanism of action data from DrugBank (Data Gap DG002)
A dedicated safety review clarifying whether anti-TNF-associated vasculitis is a class-wide paradoxical risk for golimumab specifically
Consider whether other candidates in this evidence pack with stronger, non-contradictory support — e.g. inflammatory spondylopathy (L1, Proceed with Guardrails) and polyarticular juvenile RA (L1, Proceed with Guardrails), both aligned with golimumab’s approved anti-TNF mechanism — represent better-prioritised repurposing targets than rheumatoid vasculitis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.